Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the JAK/STAT pathway in solid tumors
Zoya Qureshy, Daniel E. Johnson, Jennifer R. Grandis
Journal of Cancer Metastasis and Treatment (2020) Vol. 2020
Open Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1408
Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
Rajendra Karki, Bhesh Raj Sharma, Shraddha Tuladhar, et al.
Cell (2020) Vol. 184, Iss. 1, pp. 149-168.e17
Open Access | Times Cited: 1260
JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
Bilal Rah, Rafiq A. Rather, Gh Rasool Bhat, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 130
Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications
Karim Rihawi, Angela Dalia Ricci, Alessandro Rizzo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 3805-3805
Open Access | Times Cited: 129
The amoeboid state as part of the epithelial-to-mesenchymal transition programme
Vittoria Graziani, Irene Rodríguez‐Hernández, Óscar Maiques, et al.
Trends in Cell Biology (2021) Vol. 32, Iss. 3, pp. 228-242
Open Access | Times Cited: 108
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Greta Pessino, Claudia Scotti, Maristella Maggi
Cancers (2024) Vol. 16, Iss. 5, pp. 901-901
Open Access | Times Cited: 18
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Karan Mediratta, Sara El‐Sahli, Vanessa M. D’Costa, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3529-3529
Open Access | Times Cited: 85
Rutin (Bioflavonoid) as Cell Signaling Pathway Modulator: Prospects in Treatment and Chemoprevention
Pratibha Pandey, Fahad Khan, Huda A. Qari, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 11, pp. 1069-1069
Open Access | Times Cited: 66
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Tan-Trieu Nguyen, LeeAnn Ramsay, Mozhdeh Ahanfeshar-Adams, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 12, pp. 3432-3442
Open Access | Times Cited: 60
Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3
Qingfang Li, Yuan Cheng, Zhe Zhang, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 10
Open Access | Times Cited: 42
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Juan Mo, Stefanie L. Moye, Renée M. McKay, et al.
Oncogene (2022) Vol. 41, Iss. 9, pp. 1235-1251
Open Access | Times Cited: 40
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Jiashu Han, Mengwei Wu, Ziwen Liu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 37
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 27
Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics
Mia C. Borlongan, Hongbin Wang
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 23
Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations
Rupali Kohal, Priya Bisht, Ghanshyam Das Gupta, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107095-107095
Closed Access | Times Cited: 14
Acyltransferase zinc finger DHHC-type containing 2 aggravates gastric carcinoma growth by targeting Nrf2 signaling: A mechanism-based multicombination bionic nano-drug therapy
Luguang Liu, Longgang Wang, Liqing Liu, et al.
Redox Biology (2024) Vol. 70, pp. 103051-103051
Open Access | Times Cited: 8
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
Prachi Bajpai, Sumit Agarwal, Farrukh Afaq, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Molecular Mechanisms of Antiproliferative Effects of Natural Chalcones
Radka Michalková, Ladislav Mirossay, Maria Gazdova, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2730-2730
Open Access | Times Cited: 46
Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors
Yirivinti Hayagreeva Dinakar, Hitesh Kumar, Shyam Lal Mudavath, et al.
Life Sciences (2022) Vol. 309, pp. 120996-120996
Closed Access | Times Cited: 36
The implications of alternative pre-mRNA splicing in cell signal transduction
Sunkyung Choi, Namjoon Cho, Kee K. Kim
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 4, pp. 755-766
Open Access | Times Cited: 18
Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
Yanhong Ni, Jun T. Low, John Silke, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Proteomimetics of Natural Regulators of JAK–STAT Pathway: Novel Therapeutic Perspectives
Sara La Manna, Ilaria De Benedictis, Daniela Marasco
Frontiers in Molecular Biosciences (2022) Vol. 8
Open Access | Times Cited: 23
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer
Al‐Hassan M. Mustafa, Oliver H. Krämer
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 35-61
Closed Access | Times Cited: 22
Amoeboid migration in health and disease: Immune responses versus cancer dissemination
Samantha L. George, Joshua Alexander James Martin, Vittoria Graziani, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 10
Open Access | Times Cited: 15
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Rodrigo Entrialgo‐Cadierno, Cristina Cueto‐Ureña, Connor Welch, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top